139,015 Shares in Kenvue Inc. $KVUE Bought by Osmosis Investment Management UK Ltd

Osmosis Investment Management UK Ltd acquired a new position in Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 139,015 shares of the company’s stock, valued at approximately $2,657,000.

A number of other institutional investors have also recently bought and sold shares of the business. Johnson Financial Group Inc. bought a new position in Kenvue during the second quarter valued at about $26,000. CoreCap Advisors LLC boosted its stake in Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after acquiring an additional 591 shares during the last quarter. Elyxium Wealth LLC purchased a new position in Kenvue in the fourth quarter valued at about $26,000. Physician Wealth Advisors Inc. grew its position in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares during the period. Finally, MV Capital Management Inc. bought a new position in shares of Kenvue during the 4th quarter valued at approximately $28,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 0.1%

Kenvue stock opened at $19.08 on Monday. The firm has a 50 day simple moving average of $19.05 and a 200 day simple moving average of $18.20. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $21.78. The firm has a market capitalization of $36.65 billion, a price-to-earnings ratio of 21.93, a P/E/G ratio of 1.36 and a beta of 0.47.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). The company had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The company’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.29 EPS. On average, analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be issued a dividend of $0.21 per share. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Wednesday, August 12th. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. Kenvue’s payout ratio is currently 96.55%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on KVUE shares. UBS Group lowered their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Barclays increased their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Finally, Zacks Research cut Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.